Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial - Cortes, J.E.; Kim, D.-W.; Saikia, T.; Khattry, N.; Rathnam, K.; Alvarado, Y.; Hannah, G.; Tantravahi, S.K.; Apperley, J.F.; Charbonnier, A.; García-Gutiérrez, V.; Lucchesi, A.; et al. (The Lancet Haematology, 2025)